113 related articles for article (PubMed ID: 8562349)
21. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
22. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of bryostatin 1 in metastatic malignant melanoma.
Propper DJ; Macaulay V; O'Byrne KJ; Braybrooke JP; Wilner SM; Ganesan TS; Talbot DC; Harris AL
Br J Cancer; 1998 Nov; 78(10):1337-41. PubMed ID: 9823975
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
27. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Milandri C; Gentile A; Salzano E; Amadori D
Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
[TBL] [Abstract][Full Text] [Related]
28. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
30. Infusional vinorelbine in relapsed or refractory lymphomas.
Sarris AH; Psyrri A; Hagemeister F; Romaguera J; McLaughlin P; Rodriguez MA; Bachier C; Younes A; Mesina O; Oholendt M; Medeiros LJ; Samuels B; Adams LM; Cabanillas F
Leuk Lymphoma; 2000 Oct; 39(3-4):291-9. PubMed ID: 11342309
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN
Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
33. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
Chevallier B; Mignot L; Delozier T; Morvan F; Ferme C; Herait P
Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dolastatin-10 in patients with advanced breast cancer.
Perez EA; Hillman DW; Fishkin PA; Krook JE; Tan WW; Kuriakose PA; Alberts SR; Dakhil SR
Invest New Drugs; 2005 Jun; 23(3):257-61. PubMed ID: 15868383
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
